Amneal Pharmaceuticals (NASDAQ:AMRX) Earns Buy Rating from Analysts at StockNews.com
StockNews.com began coverage on shares of Amneal Pharmaceuticals (NASDAQ:AMRX – Free Report) in a research report report published on Wednesday. The brokerage issued a buy rating on the stock. Separately, Truist Financial raised their target price on Amneal Pharmaceuticals from $6.00 to $7.00 and gave the stock a buy rating in a research report on […]
More Stories
ACV Auctions Inc. (NASDAQ:ACVA) Receives $21.57 Consensus Target Price from Brokerages
Shares of ACV Auctions Inc. (NASDAQ:ACVA – Get Free Report) have been given a consensus rating of “Moderate Buy” by...
Patterson-UTI Energy (PTEN) to Release Earnings on Wednesday
Patterson-UTI Energy (NASDAQ:PTEN – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens...
Thoughtworks Holding, Inc. (NASDAQ:TWKS) Receives $4.18 Consensus PT from Brokerages
Shares of Thoughtworks Holding, Inc. (NASDAQ:TWKS – Get Free Report) have earned a consensus recommendation of “Hold” from the nine...
Head to Head Review: Sonoco Products (NYSE:SON) and Smurfit Westrock (NYSE:SW)
Sonoco Products (NYSE:SON – Get Free Report) and Smurfit Westrock (NYSE:SW – Get Free Report) are both industrial products companies,...
Reviewing PolyPid (NASDAQ:PYPD) and Paragon 28 (NYSE:FNA)
Paragon 28 (NYSE:FNA – Get Free Report) and PolyPid (NASDAQ:PYPD – Get Free Report) are both small-cap medical companies, but...
Critical Survey: Pangaea Logistics Solutions (NASDAQ:PANL) and Cadeler A/S (NYSE:CDLR)
Cadeler A/S (NYSE:CDLR – Get Free Report) and Pangaea Logistics Solutions (NASDAQ:PANL – Get Free Report) are both transportation companies,...